<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726582</url>
  </required_header>
  <id_info>
    <org_study_id>MCW 15565</org_study_id>
    <secondary_id>Advancing a Healthier WI</secondary_id>
    <secondary_id>FP 7718</secondary_id>
    <nct_id>NCT01726582</nct_id>
  </id_info>
  <brief_title>Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (&quot;Personalized Medicine&quot;)</brief_title>
  <official_title>A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      See treatment pathways at http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm
      :

      In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is
      cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular
      profiling). The results of the test are used by the doctor to recommend therapy (chemotherapy
      and radiation therapy) that the patient will receive before having surgery to remove the
      adenocarcinoma. When the patient goes to surgery, the adenocarcinoma that is removed is
      tested again. The results of that test are used to guide the choice of therapy after surgery.

      The chemotherapy drugs and the radiation therapy used in this clinical trial are already
      approved for treatment of pancreas cancer. This trial is intended to establish which
      treatment is best for a specific patient, based on test results from that patient's actual
      adenocarcinoma. In the past, the decision as to which treatment the patient will receive was
      not based on testing of the actual adenocarcinoma.

      Hypothesis: Resectability rate, overall survival rate and progression-free survival will be
      superior in patients with adenocarcinoma of the pancreas who receive targeted &quot;personalized&quot;
      therapy, as compared to historical data of patients who received standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resectability Rate</measure>
    <time_frame>At time of surgery</time_frame>
    <description>The primary objective is to compare the resectability rate (percent of all patients completing therapy to include surgical resection using a neoadjuvant treatment regimen selected by molecular profiling to historical results with neoadjuvant therapy and surgical resection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed up to five years</time_frame>
    <description>To compare overall survival (OS) rates of resectable and borderline resectable pancreatic cancer patients treated with molecularly targeted neoadjuvant therapy followed by surgical resection to historical controls treated with standard neoadjuvant therapy and surgical resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Assessed from first re-stage after surgery up to five years</time_frame>
    <description>To compare progression-free survival (PFS) rates of patients with resectable and borderline resectable pancreatic cancer treated with molecularly targeted neoadjuvant therapy followed by surgical resection to historical controls treated with standard neoadjuvant therapy and surgical resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency with which biomarkers can be utilized to determine treatment.</measure>
    <time_frame>At time of diagnosis and after surgery</time_frame>
    <description>To determine the frequency with which molecular profiling of a patient's tumor by IHC identifies a target for an approved, commercially-available chemotherapeutic regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the molecular profile of pretreatment biopsies and resected tumors.</measure>
    <time_frame>After surgery</time_frame>
    <description>We will compare the molecular profile obtained at time of diagnosis with the molecular profile obtained from the resected specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the the histologic treatment response to targeted chemotherapeutic regimens in resected tumors.</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Excised tumors will be evaluated for extent of histologic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the prognostic relevance of radiological response among patients undergoing neoadjuvant therapy.</measure>
    <time_frame>Ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the ability to generate primary xenografts of pancreatic cancer from resected tumors.</measure>
    <time_frame>20 weeks post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pre surgery targeted chemo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
Arm A:
Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging:
see link to protocol Figures A &amp; C at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre surgery cXRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
Arm B:
Before surgery: Chemoradiotherapy (cRXT); restaging:
see link to protocol Figure C and Figure A or B at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre surgery targeted chemo, then cXRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
Arm C1:
Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging
see link to protocol Figures B and C at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre surgery FOLFIRINOX, then cXRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
Arm C2:
standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging:
see link at protocol Figures B and C at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After surgery targeted chemo, then cXRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
Arm D1:
After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging:
see link to protocol Figures A and D at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After surgery Gemcitabine, then cXRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
Arm D2:
Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging:
see link to protocol Figures A and D at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After surgery cXRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
Arm E:
After surgery: chemoradiotherapy (cXRT); restaging:
see lint to protocol Figures A and D at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After surgery targeted chemo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
Arm F1:
Targeted chemotherapy after surgery: 8 weeks targeted chemotherapy; restaging; 8 weeks targeted chemotherapy; restaging:
see link to protocol Figure E and Figure A or B at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After surgery Gemcitabine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
Arm F2:
Gemcitabine after surgery : 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging:
see link to protocol Figure E and Figure A or B at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After surgery no additional treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
Arm G:
No additional therapy after surgery:
see link to protocol Figure E and Figure A or B at:
http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted chemotherapy prior to surgery</intervention_name>
    <description>The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.</description>
    <arm_group_label>Pre surgery targeted chemo</arm_group_label>
    <arm_group_label>Pre surgery targeted chemo, then cXRT</arm_group_label>
    <other_name>FOLFIRINOX</other_name>
    <other_name>FOLFIRI</other_name>
    <other_name>Gemcitabine with irinotecan</other_name>
    <other_name>Gemcitabine / oxaliplatin</other_name>
    <other_name>Gemcitabine / cisplatinum</other_name>
    <other_name>Gemcitabine / capecitabine</other_name>
    <other_name>Gemcitabine / nab-paclitaxel</other_name>
    <other_name>Capecitabine / nab-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard FOLFIRINOX chemotherapy prior to surgery</intervention_name>
    <description>A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.</description>
    <arm_group_label>Pre surgery FOLFIRINOX, then cXRT</arm_group_label>
    <other_name>FOLFIRINOX</other_name>
    <other_name>oxaliplatin</other_name>
    <other_name>irinotecan</other_name>
    <other_name>leucovorin</other_name>
    <other_name>5 fluoruoracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine after surgery</intervention_name>
    <description>Chemotherapy treatment with Gemcitabine.</description>
    <arm_group_label>After surgery Gemcitabine, then cXRT</arm_group_label>
    <arm_group_label>After surgery Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No additional therapy after surgery</intervention_name>
    <description>The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.</description>
    <arm_group_label>After surgery no additional treatment</arm_group_label>
    <other_name>Restaged after surgery. No additional therapy.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted chemotherapy after surgery</intervention_name>
    <description>The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.</description>
    <arm_group_label>After surgery targeted chemo, then cXRT</arm_group_label>
    <arm_group_label>After surgery targeted chemo</arm_group_label>
    <other_name>FOLFIRINOX</other_name>
    <other_name>FOLFIRI</other_name>
    <other_name>Gemcitabine with irinotecan</other_name>
    <other_name>Gemcitabine / oxaliplatin</other_name>
    <other_name>Gemcitabine / cisplatinum</other_name>
    <other_name>Gemcitabine / capecitabine</other_name>
    <other_name>Gemcitabine / nab-paclitaxel</other_name>
    <other_name>Capecitabine / nab-paclitaxel</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>Capecitabine</other_name>
    <other_name>5FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy (cXRT)</intervention_name>
    <description>A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).</description>
    <arm_group_label>Pre surgery cXRT</arm_group_label>
    <arm_group_label>Pre surgery targeted chemo, then cXRT</arm_group_label>
    <arm_group_label>Pre surgery FOLFIRINOX, then cXRT</arm_group_label>
    <arm_group_label>After surgery targeted chemo, then cXRT</arm_group_label>
    <arm_group_label>After surgery Gemcitabine, then cXRT</arm_group_label>
    <arm_group_label>After surgery cXRT</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Enrollment/ eligibility criteria:

          -  18 years of age or older

          -  Able to understand and provide written informed consent

          -  Diagnosis of adenocarcinoma of the pancreas or high suspicion of adenocarcinoma of the
             pancreas based on CT and MRI findings as detailed below by &quot;Definition of....&quot;

        Treatment Eligibility Criteria:

          -  Have an ECOG performance status less than or equal to 2

          -  Have biopsy-proven resectable or borderline resectable adenocarcinoma of the pancreas

          -  Have adequate organ and bone marrow function as defined by:

               -  total leukocytes greater than or equal to 3 x1000/μL

               -  absolute neutrophil count (ANC) &gt; or equal to 1.5x 1000/μL

               -  hemoglobin &gt; or equal to 9 g/dL

               -  platelets &gt; or equal to 100 x 1000/μL

               -  creatinine clearance &gt;60 mL/min or creatinine &lt; or equal to 1.5 mg/dL

               -  bilirubin &lt; or equal to 2 mg/dL or &gt;2 and declining as described in the protocol

               -  aspartate transaminases (AST/SGOT) &lt; or equal to3 x ULN

               -  alanine transaminases (ALT/SGPT) &lt; or equal to 3 x ULN

          -  Female patients must be post menopausal for &gt; 1 year, surgically sterile, or have a
             negative pregnancy test and used at least one form of contraception for 4 weeks prior
             to Day 1 of the study, during study treatment and during the first 4 months after
             study treatment is discontinued. Male patients must be surgically sterile or use
             barrier contraception during the study and for 4 months after the last dose of any
             study drug.

        Definition of Resectable Pancreatic Cancer includes:

          -  No evidence of extrapancreatic disease

          -  No evidence of tumor-arterial abutment (celiac, SMA or HA)

          -  If tumor induced narrowing of the SMV, PV or SMPV confluence is present it must be
             &lt;50% of the diameter of the vessel

          -  Ca 19-9 &lt;5000, when bilirubin is &lt;2 (or &gt;2 and declining as described in the protocol)

        Definition of Borderline Resectable Pancreatic Cancer to include at least one of the
        following:

          -  Tumor abutment &lt; or equal to 180 degrees of the SMA or celiac axis

          -  Tumor abutment or encasement (&gt;180 degrees) of a short segment of the HA

          -  Tumor induced narrowing of SMV, PV or SMPV of &gt;50% of the diameter of the vessel.

          -  Short segment occlusion of the SMV, PV or SMV-PV with a suitable PV above and SMV
             below, for reconstruction

          -  CT or MRI findings suspicious for, but not diagnostic of, metastatic disease (based on
             multidisciplinary assessment at the MCW weekly pancreatic cancer conference)

          -  Biopsy proven N1 disease (regional lymph nodes involved) from pre-referral biopsy or
             EUS-guided FNA

          -  Resectable tumor and CA 19-9 &gt;5000

        Exclusion Criteria:

        Any patient with one or more of the following will be excluded:

          -  Have received chemotherapy or chemoradiation within 5 years prior of study enrollment

          -  Have any previous history of another malignancy (other than cured basal or squamous
             cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of
             study enrollment

          -  Uncontrolled comorbidities including, but not limited to, ongoing or active serious
             infection, symptomatic congestive heart failure, unstable angina, unstable cardiac
             arrhythmias, psychiatric illness, excessive obesity, or situations that would limit
             compliance with the study requirements or the ability to willingly give written
             informed consent

          -  Known HIV, HBV, or HCV infection

          -  Pregnant or breast-feeding patients or any patient with child-bearing potential not
             using contraception 4 weeks prior to, during and 4 months after study treatment is
             discontinued
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas B. Evans, M.D., FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Christians, M.D., FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Tsai, M.D., M.H.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Ritch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm</url>
    <description>Link Text: Molecular Profiling to Guide Neoadjuvant Therapy -- description and decision trees</description>
  </link>
  <reference>
    <citation>Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr;16(4):836-47. doi: 10.1245/s10434-008-0295-2. Epub 2009 Feb 5.</citation>
    <PMID>19194760</PMID>
  </reference>
  <reference>
    <citation>Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 May 20;23(15):3509-16.</citation>
    <PMID>15908661</PMID>
  </reference>
  <reference>
    <citation>Staley CA, Cleary KR, Abbruzzese JL, Lee JE, Ames FC, Fenoglio CJ, Evans DB. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas. 1996 May;12(4):373-80.</citation>
    <PMID>8740405</PMID>
  </reference>
  <reference>
    <citation>De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, Pasetto L, Santantonio M, Sarti E, Mantello G, Innocente R, Frustaci S, Corvò R, Rosso R. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006 Feb;17(2):246-51. Epub 2005 Nov 9.</citation>
    <PMID>16282246</PMID>
  </reference>
  <reference>
    <citation>Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212-7.</citation>
    <PMID>17538165</PMID>
  </reference>
  <reference>
    <citation>Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20;26(21):3496-502. doi: 10.1200/JCO.2007.15.8634.</citation>
    <PMID>18640930</PMID>
  </reference>
  <reference>
    <citation>Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009 Aug 13;28(32):2903-9. doi: 10.1038/onc.2009.158. Epub 2009 Jun 22.</citation>
    <PMID>19543324</PMID>
  </reference>
  <reference>
    <citation>Kuppens IE, Beijnen J, Schellens JH. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin Colorectal Cancer. 2004 Sep;4(3):163-80. Review.</citation>
    <PMID>15377400</PMID>
  </reference>
  <reference>
    <citation>Chen G, Tian X, Liu Z, Zhou S, Schmidt B, Henne-Bruns D, Bachem M, Kornmann M. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. Br J Cancer. 2010 Jan 5;102(1):188-95. doi: 10.1038/sj.bjc.6605440. Epub 2009 Nov 17.</citation>
    <PMID>19920824</PMID>
  </reference>
  <reference>
    <citation>Réjiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia. 2009 Jul;11(7):637-50.</citation>
    <PMID>19568409</PMID>
  </reference>
  <reference>
    <citation>Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8. doi: 10.1016/j.jamcollsurg.2007.12.020. Epub 2008 Mar 17.</citation>
    <PMID>18471707</PMID>
  </reference>
  <reference>
    <citation>Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20;26(21):3487-95. doi: 10.1200/JCO.2007.15.8642.</citation>
    <PMID>18640929</PMID>
  </reference>
  <reference>
    <citation>Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13.</citation>
    <PMID>9196156</PMID>
  </reference>
  <reference>
    <citation>Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15;22(18):3776-83.</citation>
    <PMID>15365074</PMID>
  </reference>
  <reference>
    <citation>Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol. 2008 May;32(5):1091-6.</citation>
    <PMID>18425336</PMID>
  </reference>
  <reference>
    <citation>Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188. Epub 2009 Mar 9.</citation>
    <PMID>19273710</PMID>
  </reference>
  <reference>
    <citation>Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 1;29(22):3037-43. doi: 10.1200/JCO.2010.33.8038. Epub 2011 Jun 27.</citation>
    <PMID>21709185</PMID>
  </reference>
  <reference>
    <citation>Van Rijswijk RE, Jeziorski K, Wagener DJ, Van Laethem JL, Reuse S, Baron B, Wils J; EORTC GastroIntestinal Tract Cancer Cooperative Group. Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. Eur J Cancer. 2004 Sep;40(14):2077-81.</citation>
    <PMID>15341982</PMID>
  </reference>
  <reference>
    <citation>Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol. 2012 Sep 7;18(33):4533-41. doi: 10.3748/wjg.v18.i33.4533.</citation>
    <PMID>22969226</PMID>
  </reference>
  <reference>
    <citation>DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991 Dec;9(12):2128-33.</citation>
    <PMID>1960554</PMID>
  </reference>
  <reference>
    <citation>Somer BG, Schwartzbert, LS, Arena F, Epperson A, Fu D, Bortner B.V. Phase II Trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 1053</citation>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27(15 Suppl):Abstract 4525</citation>
  </reference>
  <reference>
    <citation>Conroy T, Desseigne F, Ychou M, et al. FNCLCC-FFCD PRODIGE Group. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28:15s, 2010 (suppl; abstr 4010).</citation>
  </reference>
  <reference>
    <citation>Evans DB, Christians KK and Foley WD. Pancreatectomy (Whipple Operation) and Total Pancreatectomy for Cancer. Mastery of Surgery 6th Ed. Fischer JL Ed. Wolters Kluwer/Lippincot Williams &amp; Wilkins, Philadelphia 2012; 1445-1466</citation>
  </reference>
  <reference>
    <citation>Keim R, Rao A, Von Hoff D, Evans DB, Christians KK. Molecular Profiling of Endoscopic Ultrasound (EUS) - Guided Fine Needle Aspiration (FNA) specimens in pancreas cancer: A feasibility study. Pancreas Club, Chicago, Ill; May 6-7, 2011</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Douglas B Evans, MD</investigator_full_name>
    <investigator_title>Chairman, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>molecular profile</keyword>
  <keyword>molecular profiling</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>pancreas cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>molecular target</keyword>
  <keyword>pancreas head</keyword>
  <keyword>pancreas neck</keyword>
  <keyword>pancreas uncinate</keyword>
  <keyword>pancreas body</keyword>
  <keyword>pancreas tail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

